4-溴-2,5二甲氧基苯乙胺 | 66142-81-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-2,5二甲氧基苯乙胺
• 英文名称: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane
• 英文别名: 4-bromo-2,5-dimethoxyphenethylamine；2C-B；2-(4-bromo-2,5-dimethoxyphenyl)ethanamine；2,5-dimethoxy-4-bromophenethylamine；2-(4-bromo-2,5-dimethoxyphenyl)ethan-1-amine；4-bromo-2,5-dimethoxy-β-phenethylamine
• CAS: 66142-81-2
• 化学式: C₁₀H₁₄BrNO₂
• 分子量: 260.131
• InChiKey: YMHOBZXQZVXHBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-溴-2,5二甲氧基苯乙胺 在 硼烷 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 23.0h， 生成 [2-(4-Bromo-2,5-dimethoxy-phenyl)-ethyl]-(4-fluoro-benzyl)-amine
  参考文献：
  名称：

  Influence of Amine Substituents on 5-HT2A versus 5-HT2C Binding of Phenylalkyl- and Indolylalkylamines

  摘要：

  The effect of 15 different amine substituents on 5-HT2A and 5-HT2C serotonin receptor binding was investigated for two series of compounds (i.e., phenylalkylamine and indolylalkylamine derivatives). In general, amine substitution decreases receptor affinity; however, N-(4-bromobenzyl) substitution results in compounds that bind at 5-HT2A receptors with high affinity (K-i < 1 nM) and with >100-fold selectivity. Although parallel structural modifications in the two series result in parallel shifts in 5-HT2C binding, these same modifications alter 5-HT2A binding in a less consistent manner.

  DOI：

  10.1021/jm00039a004
• 作为产物：
  描述：

  (E)-1,4-dimethoxy-2-(2-nitrovinyl)benzene 在 吡啶 、 lithium aluminium tetrahydride 、 溴 作用下， 以 四氢呋喃 为溶剂， 反应 26.5h， 生成 4-溴-2,5二甲氧基苯乙胺
  参考文献：
  名称：

  25X-BOMes和25X-NBOHs（X = H，I，Br）的合成，用于药理研究和作为法医参考标准

  摘要：

  据报道，一种快速方法可合成三种NBOH（25H-，25I-和25B-NBOH；总产率为9–38％）和三种NBOM（25H-，25I-和25B-NBOMe；总产率为7–33％）。分别来自水杨醛和2-甲氧基醛。还确定了25H-，25I-和25B-NBOH.HCl的X射线结构。我们的方法应该为制备用于药理学和法医学目的的这类物质提供一个一般的入口。

  DOI：

  10.1016/j.tetlet.2020.152804

文献信息

• HERBICIDAL AND FUNGICIDAL 5-OXY-SUBSTITUTED 3-PHENYLISOXAZOLINE-5-CARBOXAMIDES AND 5-OXY-SUBSTITUTED 3-PHENYLISOXAZOLINE-5-THIOAMIDES
  申请人：BAYER CROPSCIENCE AG

  公开号：US20150245616A1

  公开（公告）日：2015-09-03

  Herbicidally and fungicidally active 5-oxy-substituted 3-phenylisoxazoline-5-carboxamides and 5-oxy-substituted 3-phenylisoxazoline-5-thioamides of the formula (I) are described. In this formula (I), X, X 2 to X 6 , R 1 to R 4 are radicals such as hydrogen, halogen and organic radicals such as substituted alkyl. A is a bond or a divalent unit. Y is a chalcogen.

  具有除草和杀菌活性的5-氧代取代的3-苯基异噁唑啉-5-羧酰胺和5-氧代取代的3-苯基异噁唑啉-5-硫酰胺的化合物如下式（I）所述。 在这个式子（I）中，X，X2至X6，R1至R4是氢、卤素和有机基团，如取代烷基等。A是一个键或二价基团。Y是硫族元素。
• ENZYMATICALLY AND HYDROLYTICALLY STABLE RESINS, RESIN MONOMERS, AND RESIN COMPOSITES FOR USE IN DENTAL PREVENTIVE AND RESTORATIVE APPLICATIONS
  申请人：ADA Foundation

  公开号：US20150257986A1

  公开（公告）日：2015-09-17

  A composition of matter includes one or more functionalized vinylbenzyl components of the formula covalently connected to one or more R functional components; the one or more R functional groups selected from a group including one or more hydroxyl methyl (—CHOH—) moieties and/or derivatives thereof, one or more ethoxy (—CH 2 —CH 2 —O—) moieties and/or derivatives thereof, and one or more benzene (C 6 H 6 ) and/or derivatives thereof; and ether links that connect the functionalized vinylbenzyl components and the R functional components.

  一种物质的组成包括一个或多个功能化的乙烯苯基组分，其化学式为与一个或多个R功能组分共价连接；所述一个或多个R功能基从包括一个或多个羟甲基（—CHOH—）基团及/或其衍生物、一个或多个乙氧基（—CH2—CH2—O—）基团及/或其衍生物、一个或多个苯基（C6H6）及/或其衍生物的群组中选择；以及连接功能化的乙烯苯基组分和R功能组分的醚键。
• IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
  申请人：Pastor-Fernández Joaquin

  公开号：US20110269752A1

  公开（公告）日：2011-11-03

  The present invention relates to novel imidazo[1,2- b ]pyridazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

  本发明涉及新型咪唑并[1,2-b]吡啶嗪衍生物，其为磷酸二酯酶10（PDE10）的抑制剂，并且适用于治疗或预防涉及PDE10酶的神经、精神和代谢紊乱。该发明还涉及包含这种化合物的药物组合物，用于制备这种化合物和组合物的方法，以及利用这种化合物或药物组合物预防或治疗神经、精神和代谢紊乱和疾病。
• SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES
  申请人：Genoscience Pharma SAS

  公开号：EP3620164A1

  公开（公告）日：2020-03-11

  The present invention relates to novel 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments. The active compounds of the present invention can be useful as a medicament in the treatment and/or the decreasing and/or the prevention of fibrosis and/or fibrosis related diseases, or for use as a medicament in the treatment and/or the decreasing and/or the prevention of the autophagy and/or autophagy related diseases and for the inhibition of the autophagy flux, or for use in the inhibition of cathepsins B (CTSB), L (CTSL) and/or D (CTSD) and/or cathepsins B (CTSB), L (CTSL) and/or D (CTSD) related diseases; with the proviso that said compounds are not to be used for the treatment of any forms of cancers.

  本发明涉及新型2-初级氨基-4-次级氨基喹啉衍生物，其制备方法，包含它们的药物组合物以及它们作为药物的用途。本发明的活性化合物可用作药物治疗和/或减少和/或预防纤维化和/或与纤维化相关疾病，或用作药物治疗和/或减少和/或预防自噬和/或与自噬相关疾病以及抑制自噬通量，或用于抑制蛋白酶B（CTSB）、L（CTSL）和/或D（CTSD）和/或与蛋白酶B（CTSB）、L（CTSL）和/或D（CTSD）相关疾病；但所述化合物不得用于治疗任何形式的癌症。
• A process for the preparation or purification of olmesartan medoxomil
  申请人：LEK Pharmaceuticals d.d.

  公开号：EP2022790A1

  公开（公告）日：2009-02-11

  The present invention relates to a process for the preparation and purification of olmesartan medoxomil. The invention also relates to products obtainable by the process of the invention, to pharmaceutical compositions comprising the products and to their use in medicine, particularly to treat hypertension.

  本发明涉及一种用于制备和纯化奥美沙坦酯酯的方法。该发明还涉及通过该方法获得的产品，包括含有这些产品的药物组合物以及它们在医学上的应用，特别是用于治疗高血压。